1. Scrip
  2. >>Business

Patient Voice To Data: How Novartis Is Listening Up, Harnessing RWE In APMA

 
• By Anju Ghangurde

Physician-turned-pharma executive, Iris Zemzoum, leads Novartis in the Asia Pacific, Middle East and Africa (APMA) region. She tells Scrip how the Swiss group is empowering patients to help shape the future of healthcare and also partnering across the diverse region to leverage real-world evidence.

Iris Zemzoum, Novartis president for Asia Pacific, Middle East and Africa • Source: Steffen Hoeft

Not all pharma executives can perhaps relate to the patient journey as closely as Iris Zemzoum, Novartis’s president for the Asia Pacific, Middle East and Africa (APMA) region. The gynecological oncology physician-turned-pharma executive has likely seen patients in their most vulnerable state and “understands their challenges first-hand”.

It’s those kinds of sharp yet delicate insights that Zemzoum hopes to build on as companies like Novartis seek to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By Mandy Jackson

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.